AMGN Research and Charts

AMGN - Amgen Inc (Healthcare: Drug Manufacturers - General)

Projected Earnings Date: 2025-07-31 (Delayed quote data 2025-05-09)

Last 265.86	Change ⇓ -6.19 (-2.28%)	Volume 3,326,232
	Open 270.66	High 273.48	Low 265.66

8EMA (Daily) 275.04	40EMA (Daily) 287.76	50EMA (Daily) 289.32	STO (Daily) 20.869	MACD Hist (Daily) -2.171
8EMA (Weekly) 283.985	40EMA (Weekly) 293.60	50EMA (Weekly) 293.48	STO (Weekly) 21.390	MACD Hist (Weekly) -6.294


Company Profile
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.